> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-13/
- Published: 2020-02-23T12:00:00.000Z
- Updated: 2026-09-14T16:04:07.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5146163

[**Info Collection for Device Corrections/Removals**](https://www.fdaweb.com/info-collection-for-device-corrections-removals/)  
*Federal Register* notice: FDA seeks comments on an information collection extension for “Medical Devices; Reports of Corrections and Removals — 21 CFR Part 806” (OMB Control Number 0910-0359). 02/21/2020  

[**Final Rule Defines ‘Biological Product’**](https://www.fdaweb.com/final-rule-defines-biological-product/)  
*Federal Register* final rule: FDA issues a final rule to amend its regulation that defines “biological product” to incorporate changes made by legislation, and to provide the interpretation of the statutory term “protein.” 02/21/2020  

[**FDA Reclassifying Certain HIV Tests**](https://www.fdaweb.com/fda-reclassifying-certain-hiv-tests/)  
*Federal Register* proposed order. FDA proposed to reclassify certain human immunodeficiency virus (HIV) serological diagnostic and supplemental tests and HIV nucleic acid diagnostic and supplemental tests from Class 3 into Class 2\. 02/21/2020  

[**Info Collection on Custom Device Exemption**](https://www.fdaweb.com/info-collection-on-custom-device-exemption/)  
*Federal Register* notice: FDA seeks comments on an information collection extension for “Annual Reporting for Custom Device Exemption.” 02/21/2020  

[**Device Panel to Review 5 Classifications**](https://www.fdaweb.com/device-panel-to-review-5-classifications/)  
*Federal Register* notice: FDA announces a 4/23-24 Orthopedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee meeting. 02/21/2020  

[**15 ‘No Longer Marketed’ ANDAs Withdrawn**](https://www.fdaweb.com/15-no-longer-marketed-andas-withdrawn/)  
*Federal Register* notice: FDA withdraws approval of 15 ANDAs from multiple applicants after notifying the agency that they are no longer marketed. 02/21/2020  

[**Comments Reopened on Animal Drug Compounding**](https://www.fdaweb.com/comments-reopened-on-animal-drug-compounding/)  
*Federal Register* notice: FDA reopens the comment period for an 11/20/2019 notice seeking comments on “Guidance for Industry #256 — Compounding Animal Drugs from Bulk Drug Substances.” 02/20/2020  

[**Nonclinical Evaluation of Immunotoxicity Guide**](https://www.fdaweb.com/nonclinical-evaluation-of-immunotoxicity-guide/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Nonclinical Safety Evaluation of the Immunotoxic Potential of Drugs and Biologics.” 02/20/2020  

[**Panel to Review Glaxo Trelegy Ellipta sNDA**](https://www.fdaweb.com/panel-to-review-glaxo-trelegy-ellipta-snda/)  
*Federal Register* notice: FDA announces a 4/21 Pulmonary-Allergy Drugs Advisory Committee meeting to discuss a GlaxoSmithKline supplemental NDA for Trelegy Ellipta and its use for reducing all-cause mortality in COPD patients. 02/19/2020  

[**Medical Imaging Panel to Review Alzheimer’s Diagnostic**](https://www.fdaweb.com/medical-imaging-panel-to-review-alzheimers-diagnostic/)  
*Federal Register* notice: FDA announces a 4/23 Medical Imaging Drugs Advisory Committee meeting to review an Avid Radiopharmaceuticals NDA for a radioactive diagnostic agent for positron emission tomography brain imaging in Alzheimer’s patients. 02/19/2020  

[**Docket Opened for Vaping Injury Reports**](https://www.fdaweb.com/docket-opened-for-vaping-injury-reports/)  
*Federal Register* notice: FDA opens a docket to obtain information about vaping products and associated lung injuries. 02/18/2020  

[**Reg Review Period for Endorecherche’s Intrarosa**](https://www.fdaweb.com/reg-review-period-for-endorecherches-intrarosa/)  
*Federal Register* notice: FDA determines for patent extension purposes the regulatory review period for Endorecherche’s Intrarosa (prasterone). 02/18/2020  

[**Stimulant Use Disorder Drug Development Meeting**](https://www.fdaweb.com/stimulant-use-disorder-drug-development-meeting/)  
*Federal Register* notice: FDA announces a 3/10 public meeting entitled “Patient-Focused Drug Development for Stimulant Use Disorder.” 02/18/2020